vs
Bank of Marin Bancorp（BMRC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Bank of Marin Bancorp的季度营收约是REGENXBIO Inc.的1.1倍（$34.1M vs $30.3M），Bank of Marin Bancorp净利率更高（24.9% vs -221.3%，领先246.3%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 23.3%）
美 洲 河 银 行 是 一 家 社 区 银 行，1983 年 由 首 任 行 长 兼 首 席 执 行 官 Robert H. Daneke 与 首 任 董 事 会 主 席 Bill L. Withrow 共 同 创 立，服 务 于 美 国 加 利 福 尼 亚 州 大 萨 克 拉 门 托 地 区。截 至 2019 年，该 行 在 北 加 州 共 运 营 十 家 网 点，提 供 企 业 及 个 人 金 融 服 务，曾 是 American River Bankshares 的 全 资 子 公 司。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BMRC vs RGNX — 直观对比
营收规模更大
BMRC
是对方的1.1倍
$30.3M
净利率更高
BMRC
高出246.3%
-221.3%
两年增速更快
RGNX
近两年复合增速
23.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.1M | $30.3M |
| 净利润 | $8.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 24.9% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 74.5% | -31.2% |
| 每股收益（稀释后） | $0.53 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRCRGNX
| Q1 26 | $34.1M | — | ||
| Q4 25 | $27.0M | $30.3M | ||
| Q3 25 | $30.9M | $29.7M | ||
| Q2 25 | $10.3M | $21.4M | ||
| Q1 25 | $27.8M | $89.0M | ||
| Q4 24 | $22.2M | $21.2M | ||
| Q3 24 | $27.2M | $24.2M | ||
| Q2 24 | $22.5M | $22.3M |
净利润BMRCRGNX
| Q1 26 | $8.5M | — | ||
| Q4 25 | $-39.5M | $-67.1M | ||
| Q3 25 | $7.5M | $-61.9M | ||
| Q2 25 | $-8.5M | $-70.9M | ||
| Q1 25 | $4.9M | $6.1M | ||
| Q4 24 | $6.0M | $-51.2M | ||
| Q3 24 | $4.6M | $-59.6M | ||
| Q2 24 | $-21.9M | $-53.0M |
毛利率BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | -212.6% | -190.0% | ||
| Q3 25 | 31.1% | -176.3% | ||
| Q2 25 | -108.8% | -296.3% | ||
| Q1 25 | 23.3% | 13.6% | ||
| Q4 24 | 43.5% | -242.1% | ||
| Q3 24 | 25.7% | -256.6% | ||
| Q2 24 | -153.0% | -251.3% |
净利率BMRCRGNX
| Q1 26 | 24.9% | — | ||
| Q4 25 | -146.5% | -221.3% | ||
| Q3 25 | 24.3% | -208.3% | ||
| Q2 25 | -82.9% | -331.8% | ||
| Q1 25 | 17.5% | 6.8% | ||
| Q4 24 | 27.1% | -241.3% | ||
| Q3 24 | 16.8% | -246.3% | ||
| Q2 24 | -97.5% | -237.7% |
每股收益（稀释后）BMRCRGNX
| Q1 26 | $0.53 | — | ||
| Q4 25 | $-2.48 | $-1.30 | ||
| Q3 25 | $0.47 | $-1.20 | ||
| Q2 25 | $-0.53 | $-1.38 | ||
| Q1 25 | $0.30 | $0.12 | ||
| Q4 24 | $0.38 | $-0.99 | ||
| Q3 24 | $0.28 | $-1.17 | ||
| Q2 24 | $-1.36 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $394.5M | $102.7M |
| 总资产 | $3.9B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
股东权益BMRCRGNX
| Q1 26 | $394.5M | — | ||
| Q4 25 | $394.7M | $102.7M | ||
| Q3 25 | $443.8M | $161.5M | ||
| Q2 25 | $438.5M | $213.7M | ||
| Q1 25 | $439.6M | $274.2M | ||
| Q4 24 | $435.4M | $259.7M | ||
| Q3 24 | $437.0M | $301.4M | ||
| Q2 24 | $434.9M | $348.3M |
总资产BMRCRGNX
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $453.0M | ||
| Q3 25 | $3.9B | $525.2M | ||
| Q2 25 | $3.7B | $581.0M | ||
| Q1 25 | $3.8B | $490.9M | ||
| Q4 24 | $3.7B | $466.0M | ||
| Q3 24 | $3.8B | $519.1M | ||
| Q2 24 | $3.7B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | $39.1M | $-52.3M | ||
| Q3 25 | $12.5M | $-56.0M | ||
| Q2 25 | $8.0M | $-49.3M | ||
| Q1 25 | $4.9M | $33.6M | ||
| Q4 24 | $28.4M | $-31.6M | ||
| Q3 24 | $9.9M | $-40.5M | ||
| Q2 24 | $3.4M | $-45.5M |
自由现金流BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | $37.3M | $-52.8M | ||
| Q3 25 | $12.1M | $-56.5M | ||
| Q2 25 | $7.1M | $-49.7M | ||
| Q1 25 | $4.6M | $32.6M | ||
| Q4 24 | $27.8M | $-32.7M | ||
| Q3 24 | $9.8M | $-40.9M | ||
| Q2 24 | $3.4M | $-46.0M |
自由现金流率BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 138.1% | -174.0% | ||
| Q3 25 | 39.0% | -189.9% | ||
| Q2 25 | 68.7% | -232.8% | ||
| Q1 25 | 16.6% | 36.6% | ||
| Q4 24 | 125.7% | -154.2% | ||
| Q3 24 | 36.0% | -168.9% | ||
| Q2 24 | 15.0% | -206.2% |
资本支出强度BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 1.7% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 9.4% | 1.8% | ||
| Q1 25 | 1.1% | 1.2% | ||
| Q4 24 | 2.3% | 5.1% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 0.4% | 2.1% |
现金转化率BMRCRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.01× | 5.53× | ||
| Q4 24 | 4.73× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRC
| Net Interest Income | $30.3M | 89% |
| Noninterest Income | $3.8M | 11% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
